



Unique Collateral May Offer Value in Volatile Times

We see several tailwinds currently supporting the collateral performance of litigation ABS deals. Resolutions of pending cases, and the attendant plaintiff payments, should accelerate as court systems fully reopen after operating in limited capacity during the pandemic. Litigation receivables generate cashflows only following successful resolutions of the underlying claims.

In turn, rapid advancement of lawsuit outcome predictive models should inject more accuracy into cashflow projections in a sector where payments can be somewhat idiosyncratic. Some of the issuers in the fast-consolidating litigation funding industry are now employing aggregated court records and machine learning to better predict lawsuit case values. Lastly, litigation volume may rise in a recessionary or distressed economic environment, thereby expanding the collateral base for ABS transactions.¹

Such trends could further spur investor interest in a sector that can be largely uncorrelated to other securitized segments, or to the underlying interest rate environment and key economic markets such as real estate and consumer debt. Rate-driven lending pullback or recession-driven rising delinquencies should not be key drivers of litigation ABS dynamics, echoing a view we discussed for other unique securitized segments, such as [recovery bonds](#).² Rather, legislative and legal risks, as well as the specific composition of collateral pools by case type, play a bigger role in impacting the collateral performance outlook in the segment.

Issuance Volume Rises Post-Pandemic

Litigation ABS issuance picked up in 2023, with four deals pricing YTD, with a total \$481 million issued volume (Figure 1). The most recent deal, the \$119.3 million PEAR 2023-1, priced its benchmark single-A rated class at I+290bp last month.

Stav Gaon
+1 (646) 768-9173
sgaon@academysecurities.com


Headquarters Address:
Academy Securities, Inc.
622 Third Avenue, 12th Fl
New York, NY 10017

¹ The last argument may be a bit more tenuous. While intuitively a distressed economic environment may generate more conflicts that end up in the court system, we cannot immediately tie some of the common case types backing litigation ABS deals, such as auto accidents or premises liability, purely to the economy backdrop.

² "Recovery Bonds: No Need to Closely Watch the Fed or the Economy Here," Securitized Products Special Topics, Academy Securities, November 30, 2022

Litigation ABS: Tailwinds in Place for an Uncorrelated Segment

Figure 1. Litigation ABS Issuance and Spreads



Source: Bloomberg and Academy Securities

Aspects to Track on Litigation ABS Deals

The elevated uncertainty around legal case outcomes puts a particular emphasis on the **receivable pool diversification**. Pools are diversified across many aspects, as recent deals demonstrate, including by case type, state, and payment sources (typically insurance firms). Deal documents also include long lists of so-called concentration limits, designed to ensure diverse exposures. We see concentration limits on aspects such as exposure to specific lawyer or law firm (for example, capped at 12.0% of the aggregate outstanding receivable principal balance), or to single payment source (example cap of 15.0%), among dozens other limits. Other aspects to note include:

- Litigation vs. medical receivables.** The lion's share of receivables on litigation ABS deals comprises of advances to plaintiffs or lawyers in connection with potential future settlements. Some deals also include medical receivables – advances to medical providers in connection with medical services. The medical service providers (MSP) may later recover payments from case settlements. For example, in Libra 2023-1, 58.8% of the pool is litigation receivables and the remainder is medical receivables (Figure 2). Pear 2023-1 also contains a small sleeve of medical receivables. The presence of medical receivables may offer investors another diversification aspect. But deal documents and presale reports show that the underwriting and analysis approach to medical receivables is different from litigation receivables, adding a potential hurdle to investors not steeped in the sector.

Litigation ABS: Tailwinds in Place for an Uncorrelated Segment


Figure 2. Litigation ABS Pool Characteristics

	Pear 2023-1	LFS 2023A	Cartiga 2023-1	Libra 2023-1	Libra 2022-2	LFS 2022A
Issuer	Golden Pear Funding	US Claims Holdings	Cartiga Asset Management	Libra Solutions	Libra Solutions	US Claims Holdings
Price Date	7/14/2023	5/22/2023	2/16/2023	2/8/2023	9/30/2022	5/11/2022
Pool Balance (\$MM)	119.3	143.8	103.4	76.5	74.0	87.0
ADPB (\$MM)	119.6	165.0	139.8			99.2
Overcollateralization (%)		12.9		10.3		
Number of Individual Advances		13,817		95,519	90,388	6,878
Number of Unique Plaintiff or Vendor Advances		6,462		16,445	16,488	4,263
Number of Unique Lawyer Advances		18				16
Litigation Receivables (%)	95.7	100.0		58.8	60.8	100.0
Medical Receivables (%)	4.3	0.0		41.2	39.2	0.0

Source: Deal Documents, Presales, and Academy Securities

- Case type concentration.** Across litigation receivables, deals vary in their case types (Figure 3). For example, in Libra 2023-1 the dominant case type is auto-related, comprising over two-thirds of the litigation funding receivables. In LFS 2023-A motor vehicle accidents also comprise a significant share of the pool (34.2%), but two other case types - premises liability (25.3%) and work related (23.9%) – have a larger combined exposure. Presales suggest that the mix of case types in Libra and LFS is typical in the litigation finance sector. But such differences across deals in case type breakdowns do suggest some deals may be more sensitive to legal risks and uncertainty associated with specific case types.

Figure 3. Litigation ABS Case Type and State Exposure Breakdowns



Source: Deal Documents, Presales, and Academy Securities

- State exposure.** Varying state concentrations across deals can elevate risks in particular deals, amid different local legal jurisdictions. One notable case study is a tort reform in Florida (HB 837) that became effective on March 24, 2023. The law’s stated goal is to decrease frivolous lawsuits and limit personal injury cases, insurance litigation, and attorneys’ fees. Underscoring the potential impact of the law on the litigation funding industry, on the eve of HB 837’s enactment, plaintiffs’ lawyers filed more than 280,000 new cases.

Academy Securitized Products Research Recent Reports

Securitized Products Special Topics:

[Agency Floaters: Adjusting Interest Rate Cap Escrows](#)

[Equipment ABS: Pick Your Spots Amid Diverging Collateral Trends](#)

[Commercial Solar ABS: Emergent Segment to Alleviate Headline Risks](#)

[Multifamily CRT: Limited Credit Risk on Synthetic Exposures](#)

[OC Triggers: Subtle Thresholds Come to the Fore As Collateral Stress Builds Up](#)

[Cell Towers: Lender-Friendly Features Dovetail with Secular Tailwinds](#)

[Timeshare ABS: Exposure to Favorable Hospitality Segments](#)

[Self Storage: Aspects to Watch as Performance Decelerates](#)

[Transitional Multifamily: Collateral Migration Away from CRE CLO Offers Different Deal Profile](#)

[Recovery Bonds: No Need to Closely Watch the Fed or the Economy Here](#)

[Affordable Mortgages: Fee Elimination Spotlights Convexity Profile](#)

[Investor Non-QM: Rental Exposure with Some Structural Twists](#)

[Data Centers: A Strong Segment Juggles ABS and CMBS](#)

[Small Balance Multifamily: Value Ahead of Slow Prepays](#)

[Future Funding: Potential Key Performance Driver as CRE CLO Pipeline Builds Up](#)

[Multifamily Prepays: Property Sales Trigger Paydowns](#)

[Manufactured Housing: Resilient Segment Amid Potential Multifamily Softness](#)

[Tender Offers: Expect More to Come, Though Not on a Predictable Schedule](#)

[NYC Multifamily: Rent Increases to Support Cashflows Amid Regulatory Restrictions](#)

[Housing at a Crossroads: Single-family and Multifamily Exposures](#)

[Senior Housing: Focus on Segment Selection Amid Pandemic Impact](#)

[Disaster Performance: Pandemic Forbearance Resolutions Bode Well for Future Stresses](#)

[Russian Sanctions Impact: Lease Terminations and Forced Property Sales](#)

CMBS Credit Focus:

[Securitized Mezz: Workout Dynamics in Public Display](#)

[Dark Triggers: Nuances in Focus as Tenant Departures and Subleasing Pick Up](#)

[Upping Appraisals: Recovering Valuations Reverse Shortfalls](#)

[Non-Recoverable Advances: Unveiling a Rationale for a Key Decision](#)

[Excess Cash Allocations: Probing Advances on Positive Cashflowing Loans](#)

[Release Prices: Cherry Picking Across Office Portfolios, Sometimes at a Discount](#)

[Mezz Loan Sales: A Potential Headache for CMBS Workouts](#)

[Equity Pledges: Hotel Bossert Spotlights Dual Collateralized Loans](#)

[The Road to Conversion: Consider Office Ground Leases and ARD Loans](#)

[Credit 2023: Advancing and Workout Approaches to Play a Central Role](#)

[Hotel Receiverships: Palmer House Hilton Spotlights Stabilization Efforts](#)

[Office Modifications: 285 Madison May Offer a Blueprint for More to Come](#)

[Triple-A Shortfalls: Destiny Spotlights Delayed ASERs Impact](#)

[Inflation-Resistant Leases: Rent Steps Offer Some Revenue Protection, though Not Much](#)

[Industrial Delinquencies: Don't Happen Often, but Watch Closely When They Do](#)

[Hotel Reserves: Key Performance Driver after Pandemic-Driven Depletion](#)

[Government Tenants: Short Termination Notices and Specialized Properties](#)

[Mall Foreclosures: What to Track as Servicers May Shift Away from Modifications](#)

Disclaimer

Although certain information has been obtained from sources believed to be reliable, we do not guarantee its accuracy, completeness or fairness. We have relied upon and assumed without independent verification, the accuracy and completeness of all information available from public sources.

Views and opinions expressed are for informational purposes only and do not constitute a recommendation by Academy Securities for any purpose including buying, selling, or holding any security. Views and opinions are current as of the date of this presentation and may be subject to change, they should not be construed as investment advice.

This information discusses general market activity, industry or sector trends, or other broad-based business, economic, market or political conditions and should not be construed as operational, research or investment advice. This material has been prepared by Academy Securities and is not financial research nor a product of Academy Securities. It was not prepared in compliance with applicable provisions of law designed to promote the independence of financial analysis and is not subject to a prohibition on trading following the distribution of financial research. The views and opinions expressed may differ from those of Academy Securities. Investors are urged to consult with their financial advisors before buying or selling any securities. This information may not be current and Academy Securities has no obligation to provide any updates or changes.

Economic and market forecasts presented herein reflect a series of assumptions and judgments as of the date of this presentation and are subject to change without notice. These forecasts do not take into account the specific investment objectives, restrictions, tax and financial situation or other needs of any specific client. Actual data will vary and may not be reflected here. These forecasts are subject to high levels of uncertainty that may affect actual performance. Accordingly, these forecasts should be viewed as merely representative of a broad range of possible outcomes. These forecasts are estimated, based on assumptions, and are subject to significant revision and may change materially as economic and market conditions change. Academy Securities has no obligation to provide updates or changes to these forecasts. Case studies and examples are for illustrative purposes only.

Index Benchmarks

Indices are unmanaged. The figures for the index reflect the reinvestment of all income or dividends, as applicable, but do not reflect the deduction of any fees or expenses which would reduce returns. Investors cannot invest directly in indices.

The indices referenced herein have been selected because they are well known, easily recognized by investors, and reflect those indices that the Investment Manager believes, in part based on industry practice, provide a suitable benchmark against which to evaluate the investment or broader market described herein. The exclusion of “failed” or closed hedge funds may mean that each index overstates the performance of hedge funds generally.

THIS MATERIAL DOES NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY JURISDICTION WHERE OR TO ANY PERSON TO WHOM IT WOULD BE UNAUTHORIZED OR UNLAWFUL TO DO SO.

©Academy Securities, Inc.